Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P56524

UPID:
HDAC4_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
P56524; E9PGB9; F5GX36; Q86YH7; Q9UND6

BACKGROUND:
Histone deacetylase 4, a crucial enzyme in epigenetic repression, is responsible for the deacetylation of histones, affecting transcriptional regulation and developmental processes. Its interaction with myocyte enhancer factors such as MEF2A, MEF2C, and MEF2D is vital for muscle maturation. Additionally, HDAC4's involvement in the regulation of ESR1 expression in breast cancer through MTA1-mediated pathways and its deacetylation of HSPA1A and HSPA1B at 'Lys-77' demonstrate its broad biological significance.

THERAPEUTIC SIGNIFICANCE:
The association of Histone deacetylase 4 with a specific neurodevelopmental disorder highlights its potential as a target for therapeutic development. Understanding the role of Histone deacetylase 4 could open doors to potential therapeutic strategies, particularly in the context of genetic diseases characterized by developmental delays and seizures.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.